CJC-1295 With DAC vs. Without DAC: The Half-Life Difference Explained

"CJC-1295 with DAC" and "CJC-1295 without DAC" are, functionally, two different molecules that get discussed under the same trade name. Understanding the difference comes down to a single engineering choice — the Drug Affinity Complex (DAC) — and how it changes the peptide's half-life from roughly 30 minutes to roughly 6-8 days.

The baseline: GHRH and its limits

CJC-1295 is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH). Natural GHRH is a 44-amino-acid peptide released by the hypothalamus that binds GHRH receptors on pituitary somatotrophs and triggers GH release. Its natural half-life is measured in minutes — it is rapidly cleaved by dipeptidyl peptidase-IV (DPP-IV) at the second position and cleared.

Modified GRF 1-29 (aka "CJC-1295 without DAC")

"CJC-1295 no-DAC" is technically a misnomer — the correct scientific name is Modified GRF 1-29 (or Tetrasubstituted GRF 1-29). It uses the first 29 amino acids of natural GHRH (which retain full receptor activity) plus four specific substitutions to block DPP-IV cleavage:

• Position 2: Ala → D-Ala
• Position 8: Asn → Gln
• Position 15: Gly → Ala
• Position 27: Met → Leu

Reported half-life: roughly 30 minutes. That is 10× the ~3-minute native GHRH half-life, but still short enough to preserve pulsatile GH release — the peptide triggers a sharp pituitary pulse, is cleared, and pituitary function returns to baseline.

Adding DAC — the albumin-binding modification

DAC (Drug Affinity Complex) is a reactive maleimidoproprionic-acid linker developed by ConjuChem. When attached to Modified GRF 1-29, it covalently binds circulating serum albumin at cysteine-34 in the bloodstream. The mechanism produces three effects:

1. Enzymatic shielding — bound to a ~66 kDa albumin molecule, the peptide is sterically protected from proteases including DPP-IV.
2. Delayed renal clearance — the albumin-peptide complex is far too large to be filtered by the glomerulus.
3. Sustained receptor engagement — the tethered peptide continues to interact with pituitary GHRH receptors as long as the albumin complex circulates.

The reported half-life of DAC-modified CJC-1295: approximately 6-8 days from a single subcutaneous dose.

Pulsatile vs continuous GH release

This is the biologically meaningful difference between the two variants:

• Mod GRF 1-29 (no DAC) produces a sharp, ~30-minute GHRH signal — a defined pulse followed by baseline recovery. This is closer to native physiology, where GH release is pulsatile and dominated by nocturnal slow-wave-sleep bursts.
• CJC-1295 with DAC produces a continuous elevation of GHRH receptor activation over many days — sometimes described in research literature as a "GH bleed." Baseline GH and IGF-1 are raised, but the natural pulsatile pattern is flattened.

GHRP synergy applies to both

Both variants are frequently paired with a GHRP (Growth Hormone Releasing Peptide) such as Ipamorelin or GHRP-6. GHRPs act at the ghrelin receptor to inhibit somatostatin — the physiological "brake" on GH release. Because CJC-1295/Mod GRF 1-29 acts on the GHRH pathway and GHRPs act on the ghrelin/somatostatin pathway, the two work through independent mechanisms and produce a synergistic (not merely additive) increase in GH release.

Trade-off summary

Why most current research favours the no-DAC variant

Recent published research in the growth-hormone-axis space has trended toward the pulsatile Mod GRF 1-29 approach because it preserves the endogenous rhythm of GH release. Continuous DAC-driven elevation is more likely to blunt natural pulsatility, potentially desensitise pituitary receptors, and — because GH is counter-regulatory to insulin — may confound insulin-sensitivity endpoints in metabolic-pathway studies.

Research use only

All content is mechanism-level and pharmacokinetic in nature, provided for in-vitro laboratory research and educational study.

For laboratory and research use only. Not for human consumption.